Literature DB >> 2816872

Methemalbumin in acute pancreatitis: an evaluation of its prognostic value and comparison with multiple prognostic parameters.

P G Lankisch1, C A Schirren, J Otto.   

Abstract

Methemalbumin (MHA) and Ranson's prognostic parameters were measured in 90 patients with acute pancreatitis. Thirteen died (14.4%). The mortality rate was 36% in MHA-positive versus 6.2% in MHA-negative patients. Severe renal (56% vs 18.5%) and pulmonary (44% vs 10.2%) complications occurred more frequently in the MHA-positive as compared with the MHA-negative group. Hemorrhagic pancreatitis was found in all MHA-positive patients who were subject to surgery or postmortem examination. By way of comparison, the presence of more than four Ranson signs was associated with about the same risk of mortality and the development of complications as positive MHA findings. There was a good correlation between single and multiple prognostic factors for slight but not for moderate-severe or severe cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2816872

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

1.  Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis.

Authors:  S Tenner; C Fernandez-del Castillo; A Warshaw; W Steinberg; J Hermon-Taylor; J E Valenzuela; M Hariri; M Hughes; P A Banks
Journal:  Int J Pancreatol       Date:  1997-04

Review 2.  Prognostic factors in acute pancreatitis.

Authors:  P Malfertheiner; J E Domínguez-Muñoz
Journal:  Int J Pancreatol       Date:  1993-08

3.  JPN Guidelines for the management of acute pancreatitis: severity assessment of acute pancreatitis.

Authors:  Masahiko Hirota; Tadahiro Takada; Yoshifumi Kawarada; Koichi Hirata; Toshihiko Mayumi; Masahiro Yoshida; Miho Sekimoto; Yasutoshi Kimura; Kazunori Takeda; Shuji Isaji; Masaru Koizumi; Makoto Otsuki; Seiki Matsuno
Journal:  J Hepatobiliary Pancreat Surg       Date:  2006
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.